Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Oct;20(5):283-90.
doi: 10.1016/j.ctim.2012.04.002. Epub 2012 Apr 27.

Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer

Juliann Saquib  1 , Barbara A Parker, Loki Natarajan, Lisa Madlensky, Nazmus Saquib, Ruth E Patterson, Vicky A Newman, John P Pierce
Affiliations
Randomized Controlled Trial

Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer

Juliann Saquib et al. Complement Ther Med. 2012 Oct.

Abstract

Objective: The purpose of this study was to assess whether CAM use affected breast cancer prognosis in those who did not receive systemic therapy.

Design: Secondary data analysis of baseline/survey data from the Women's Healthy Eating and Living (WHEL) study. 2562 breast cancer survivors participating in the study completed baseline assessments and a CAM use questionnaire. Cox regression models were conducted to evaluate the use of CAM modalities and dietary supplements on time to an additional breast cancer event (mean follow-up=7.3 years).

Setting: A US-based multi-site randomized dietary trial.

Outcome: Time to additional breast cancer events.

Results: The women who did not receive any systemic treatment had a higher risk for time to additional breast cancer events (HR=1.9, 95% CI: 1.32, 2.73) and for all-cause mortality (HR=1.7, 95% CI: 1.06, 2.73) compared to those who had received systemic treatment. Among 177 women who did not receive systemic treatment, CAM use was not significantly related to additional breast cancer events. There were no significant differences between high supplement users (≥3 formulations per day) and low supplement users in either risk for additional breast cancer events.

Conclusion: The risk for an additional breast cancer event and/or death was higher for those who did not receive any systemic treatments; the use of dietary supplements or CAM therapies did not change this risk. This indicates that complementary and alternative therapies did not alter the outcome of breast cancer and should not be used in place of standard treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of the number of supplement formulations used by a cohort of breast cancer survivors enrolled in the WHEL Study
See this image and copyright information in PMC

References

    1. Ries L, Eisner M. SEER Survival Monograph: Cancer Survival Among Adults: Cancer SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute; Bethesda, MD: 2007. pp. 07–6215.
    1. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356:2399–2405. - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med. 1995;333:1444–1455. - PubMed
    1. Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol. 2009;27:5160–5167. - PMC - PubMed
    1. Polacek GN, Ramos MC, Ferrer RL. Breast cancer disparities and decision-making among U.S. women. Patient Educ Couns. 2007;65:158–165. - PubMed

Publication types